After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial
DalCor Pharmaceuticals has regrouped from past setbacks to complete an $80 million Series D round to advance its cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, to Phase III for reducing myocardial infarction.
The company’s previous attempt at a registrational trial for dalcetrapib ended in disappointment, likely due to the negative effects of the Covid pandemic. Despite a primary endpoint miss, the results of dal-GenE were promising, and DalCor is now giving it another go.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.